AxoGen price target raised to $26 from $22 at Canaccord

Canaccord raised the firm’s price target on AxoGen (AXGN) to $26 from $22 and keeps a Buy rating on the shares. The firm said they posted strong Q4 results as the company notes its positive performance reflects ongoing improvements in commercial execution, including its focus on high-potential accounts along with adoption of AXGN’s algorithm across procedures.